Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS esophageal and gastric cancer umbrella study
MOH_2020-07-14_008952Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Jun 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, tiragolumab, cisplatin and fluorouracil in esophageal cancer (4 arms), sponsored by Roche. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
atezolizumabtiragolumabcisplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on MOH_2020-07-14_008952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-14_008952.